Evidence map›Paper›PMID 29245086›Full record

ArticleJournal of pharmaceutical and biomedical analysis2018

Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma.

Susan Christner, Jianxia Guo, Robert A Parise, Melanie Ringeval, Adam T Hoye, Peter Wipf, Michael W Epperly, Joel S Greenberger, Jan H Beumer, Julie L Eiseman

Abstract readValidation Study
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Susan ChristnerCancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Jianxia GuoCancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Robert A PariseCancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Melanie RingevalCancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Adam T HoyeDepartment of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Peter WipfCancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Michael W EpperlyDepartment of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Joel S GreenbergerDepartment of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Jan H BeumerCancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: beumerj@gmail.com.
Julie L EisemanCancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
Training and EducationU19AI068021 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GREENBERGER, JOEL S · 2005 to 2019
$44.4M
Cancer Pharmacokinetics Research SpecialistR50CA211241 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARISE, ROBERT · 2016 to 2025
$1.8M
NCI NIH HHS P30 CA047904NCI NIH HHS R50 CA211241NIAID NIH HHS U19 AI068021
6 · The paper itself

Abstract

JP4-039 radio-protects prior to, and radio-mitigates after ionizing radiation by neutralizing reactive oxygen species. We developed and validated an LC-MS/MS assay for the quantitation of JP4-039 in murine plasma. Methanol protein precipitation of 50μL plasma was followed by isocratic reverse phase chromatography for a 6min run time, and electrospray positive mode ionization mass spectrometric detection. The plasma assay was linear from 1 to 1000ng/mL with appropriate accuracy (97.1-107.6%) and precision (3.7-12.5%CV), and fulfilled FDA guidance criteria. Recovery was 77.2-136.1% with moderate ionization enhancement (10.9-39.5%). Plasma freeze-thaw stability (98.8-104.2%), stability for 13.5 months at -80°C (93.1-105.6%), and stability for 4h at room temperature (94.2-97.6%) were all acceptable. Limited cross-validation to tissue homogenates suggested that these could also be analyzed for JP4-039 accurately. This assay has been directly applied to determine the pharmacokinetics of JP4-039 in C57BL/6 male mice after IV administration of 20mg/kg JP4-039 and will be extended to other studies of this agent.

Indexed as

Chromatography, Reverse-PhaseSpectrometry, Mass, Electrospray IonizationTandem Mass SpectrometryAdministration, IntravenousAnimalsCalibrationCold TemperatureDrug MonitoringDrug StabilityMaleMice, Inbred C57BLNitrogen OxidesRadiation-Protective AgentsReference StandardsReproducibility of ResultsJP4-039Nitrogen OxidesRadiation-Protective AgentsAssayHydroxylamine speciesJP4-039MiceNitroxideOxoammonium cationPharmacokineticsRadiation mitigationRadiation protectionTandem mass spectrometryValidation

Identifiers

PMID29245086
PMCPMC5767136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.